STOCK TITAN
  1. Home
  2. News
  3. ORYZF

Oryzon Genomics S.A. - ORYZF STOCK NEWS

IMPACT
SENTIMENT
ORYZF : OTC
ORYZON Presents Safety and Efficacy Data of Vafidemstat From the Phase II ESCAPE Trial in Severe COVID-19 Patients at ECCMID-2021
covid-19
IMPACT
SENTIMENT
ORYZF : OTC
ORYZON to Present New Clinical Data and Corporate Updates at International Conferences in June and July
conferences clinical trial
IMPACT
SENTIMENT
ORYZF : OTC
ORYZON announces FDA approval of IND for PORTICO, a Phase IIb trial with vafidemstat in Borderline Personality Disorder
fda approval
IMPACT
SENTIMENT
ORYZF : OTC
ORYZON Presents Iadademstat ALICE 30-Month Data at EHA-2021, Confirming Positive and Robust Efficacy in Combination with Azacitidine in AML
IMPACT
SENTIMENT
ORYZF : OTC
ORYZON to Present New Clinical Data and Corporate Updates at International Conferences in May and June
conferences clinical trial
IMPACT
SENTIMENT
ORYZF : OTC
ORYZON Reports Results and Corporate Update for Quarter Ended March 31, 2021
IMPACT
SENTIMENT
ORYZF : OTC
ORYZON Starts Preclinical Collaboration on Autism with the Seaver Autism Center at Mount Sinai
IMPACT
SENTIMENT
ORYZF : OTC
ORYZON Enrolls First Patient in PORTICO, a Phase IIb Clinical Trial With Vafidemstat in Borderline Personality Disorder
clinical trial
Stock ORYZF logo
Oryzon Genomics S.A.

OTC:ORYZF

ORYZF Rankings

#4822 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ORYZF Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Health Technology, Biotechnology
Spain
Cornella De Llobregat